Nemecko - nemčina - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

ferring gmbh (3076475) - carbetocin - injektionslösung - teil 1 - injektionslösung; carbetocin (24120) 0,1 milligramm

Belgicko - nemčina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

ferring - carbetocin - injektionslösung - 100 µg/ml - carbetocin 100 µg/ml - carbetocin

Švajčiarsko - nemčina - Swissmedic (Swiss Agency for Therapeutic Products)

ferring ag - carbetocinum - injektionslösung - carbetocinum 100 µg, acidum succinicum, mannitolum, methioninum, natrii hydroxidum q.s. ad ph, aqua ad iniectabile q.s., ad solutionem pro 1 ml corresp. natrium 0.386 mg. - prävention uteriner blutungen aufgrund einer postpartalen uterusatonie - biotechnologika

Rakúsko - nemčina - AGES (Agentur für Gesundheit und Ernährungssicherheit)

ferring arzneimittel ges.m.b.h - carbetocin - carbetocin

Nemecko - nemčina - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

eurimpharm arzneimittel gmbh - carbetocin - injektionslösung - carbetocin 0.1mg

Nemecko - nemčina - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

diapharm gmbh & co. kg - 2-hydroxybenzoesäure-kaliumsalz - dragees - 2-hydroxybenzoesäure-kaliumsalz 300.mg

Nemecko - nemčina - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

diapharm gmbh & co. kg - ascorbinsäure, natriumsalicylat, 4-aminobenzoesäure-natriumsalz - dragees - ascorbinsäure 50.mg; natriumsalicylat 300.mg; 4-aminobenzoesäure-natriumsalz 300.mg

Európska únia - nemčina - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antithrombotische mittel - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Belgicko - nemčina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz - rivaroxaban - filmtablette - 10 mg - rivaroxaban 10 mg - rivaroxaban

Belgicko - nemčina - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

sandoz - rivaroxaban - filmtablette - 15 mg - rivaroxaban 15 mg - rivaroxaban